Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.
Andrew Satlin, MD
Advertisement
Articles by Andrew Satlin, MD
Advertisement
Latest Updated Articles
FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer DiseasePublished: August 29th 2025 | Updated: September 2nd 2025
Indirect Comparison Study Hints at Lower ARIA and ICH-Related Mortality Risk in Lecanemab Over DonanemabPublished: July 28th 2025 | Updated: July 30th 2025
Observed Differences in PIRA Definition Call for More Standardized Agreement on TermPublished: May 14th 2025 | Updated: May 16th 2025
Serum Neurofilament Light Chain Limited in Predicting MOGAD Attacks but Correlates With Attack SeverityPublished: May 12th 2025 | Updated: May 13th 2025
- FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
Published: March 27th 2025 | Updated: March 28th 2025
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion CountsPublished: March 4th 2025 | Updated: March 19th 2025
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
International Committee Publishes 2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis
2
New Study Finds Link Between Gut Hormone GLP-1 and NMOSD Symptoms, Paving Way for Targeted Treatments
3
RELIEV-CM Pilot Study Data Further Supports ShiraTronics’ Neuromodulation Device to Treat Chronic Migraine
4
SKY-0515 Demonstrates Dose-Dependent Reductions in Mutant Huntingtin Protein in Phase 1 Update
5
